Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid) in Patients With Essential Tremor: An Open-Label Dose Continuation Study.

Trial Profile

Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid) in Patients With Essential Tremor: An Open-Label Dose Continuation Study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2013

At a glance

  • Drugs T 2000 (Primary)
  • Indications Essential tremor
  • Focus Therapeutic Use
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 26 Dec 2013 Actual end date added as 1 December 2009 as reported in ClinicalTrials.gov record.
    • 26 Dec 2013 Status changed from suspended to discontinued as reported in ClinicalTrials.gov record.
    • 06 May 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top